Clemens Schödl, general manager of Gilead Austria, discusses Gilead’s footprint and reputation in Austria as the leading global player in HIV treatment and what must be done to bring Austrian innovation into a new era to fully leverage Gilead’s life changing treatments.
As general manager, could you introduce our international readers to Gilead Austria?
"We are in the process of evolving our communications approach to be more open and proactive."
Joy Ladurner, co-director of the NKSE (National Coordination Center for Rare Diseases) in Austria, discusses the rationale behind Austria’s prioritization of rare diseases and its leading role in the field.…
Alexander Biach, chairman of the Main Association of Austrian Social Security Institutions, discusses handling the responsibility for Austria’s Europe-leading social security coverage, current inefficiencies that need to be ironed out,…
Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian affiliate within the global group, organizational restructuring, and the receptiveness of Austria to UCB’s innovative…
In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz – the generics arm of global giant Novartis – has moved…
Like a family recipe that has been refined and perfected over countless generations, Austria has developed a reputation as the quintessential clinical trials destination; a perfect combination of world-class academia,…
Austria has long been merely a cog in the wheel of global R&D, lying in the shadows of neighboring research giants, Germany and Switzerland. Now, however, this perception is changing…
See our Cookie Privacy Policy Here